S100A8/9 dimers were reported to promote tumor cell proliferation by creating a pro-inflammatory microenvironment and contribute to disease progression in MPN, whereas tasquinimod, an S100A8/S100A9 inhibitor, inhibited the MPN phenotype [34–36]. Here, S100A8 is linked to myeloproliferative disorder.